Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
- PMID: 32291137
- PMCID: PMC7151347
- DOI: 10.1016/j.jaut.2020.102452
Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
Abstract
The emergent outbreak of coronavirus disease 2019 (COVID-19) has caused a global pandemic. Acute respiratory distress syndrome (ARDS) and multiorgan dysfunction are among the leading causes of death in critically ill patients with COVID-19. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome (CRS), may play a major role in the pathology of COVID-19. However, the efficacy of corticosteroids, commonly utilized antiinflammatory agents, to treat COVID-19-induced CRS is controversial. There is an urgent need for novel therapies to treat COVID-19-induced CRS. Here, we discuss the pathogenesis of severe acute respiratory syndrome (SARS)-induced CRS, compare the CRS in COVID-19 with that in SARS and Middle East respiratory syndrome (MERS), and summarize the existing therapies for CRS. We propose to utilize interleukin-6 (IL-6) blockade to manage COVID-19-induced CRS and discuss several factors that should be taken into consideration for its clinical application.
Keywords: Coronavirus disease 2019; Cytokine release syndrome; Interleukin-6; Tocilizumab.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest No potential conflicts of interest relevant to this review were reported.
Similar articles
-
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.Proc Natl Acad Sci U S A. 2020 Sep 8;117(36):22351-22356. doi: 10.1073/pnas.2010229117. Epub 2020 Aug 21. Proc Natl Acad Sci U S A. 2020. PMID: 32826331 Free PMC article.
-
Cytokine release syndrome in severe COVID-19.Science. 2020 May 1;368(6490):473-474. doi: 10.1126/science.abb8925. Epub 2020 Apr 17. Science. 2020. PMID: 32303591 No abstract available.
-
IL-6: Relevance for immunopathology of SARS-CoV-2.Cytokine Growth Factor Rev. 2020 Jun;53:13-24. doi: 10.1016/j.cytogfr.2020.05.009. Epub 2020 May 20. Cytokine Growth Factor Rev. 2020. PMID: 32475759 Free PMC article. Review.
-
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.Front Immunol. 2020 Jun 16;11:1445. doi: 10.3389/fimmu.2020.01445. eCollection 2020. Front Immunol. 2020. PMID: 32612616 Free PMC article. No abstract available.
-
The COVID-19 Cytokine Storm; What We Know So Far.Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020. Front Immunol. 2020. PMID: 32612617 Free PMC article. Review.
Cited by
-
SARS-CoV-2 spike protein induces the cytokine release syndrome by stimulating T cells to produce more IL-2.Front Immunol. 2024 Sep 18;15:1444643. doi: 10.3389/fimmu.2024.1444643. eCollection 2024. Front Immunol. 2024. PMID: 39359733 Free PMC article.
-
Acute estradiol and progesterone therapy in hospitalized adults to reduce COVID-19 severity: a randomized control trial.Sci Rep. 2024 Sep 30;14(1):22732. doi: 10.1038/s41598-024-73263-5. Sci Rep. 2024. PMID: 39349554 Free PMC article. Clinical Trial.
-
Assessment of myocardial injury by SPECT myocardial perfusion imaging in patients with COVID-19 infection in a single center after lifting the restrictions in China.Ann Nucl Med. 2024 Aug 26. doi: 10.1007/s12149-024-01970-0. Online ahead of print. Ann Nucl Med. 2024. PMID: 39186242
-
Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review.Eur J Clin Pharmacol. 2024 Oct;80(10):1523-1530. doi: 10.1007/s00228-024-03719-0. Epub 2024 Jun 27. Eur J Clin Pharmacol. 2024. PMID: 38926166
-
A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.Curr Top Med Chem. 2024;24(21):1883-1916. doi: 10.2174/0115680266296095240529114058. Curr Top Med Chem. 2024. PMID: 38859776 Review.
References
-
- WHO . 2020. Coronavirus Disease 2019 (COVID-19) Situation Report – 67.
-
- T. Novel Coronavirus Pneumonia Emergency Response Epidemiology Novel Coronavirus Pneumonia Emergency Response Epidemiology. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China] Zhonghua Liuxingbingxue Zazhi. 2020;41:145–151. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous